
Unicycive Therapeutics Faces Securities Class Action Over FDA Delays
Investors who incurred losses on Unicycive Therapeutics stock between December 29, 2025, and June 29, 2026, are being sought to serve as lead plaintiffs in a securities fraud class action lawsuit. The case centers on allegations that the company misled shareholders regarding its manufacturing oversight and regulatory readiness.

























